Hadasit, the technology transfer company of Jerusalem-based Hadassah Medical Organization, announced the successful pre-clinical testing of a prototype of its Double Lumen PCI Guiding Catheter for use in the treatment of coronary artery disease. Unlike conventional catheters, the device has two lumens rather than one, allowing for continuous medication infusion to the coronary artery during percutaneous coronary intervention (PCI). “There are currently only two options by which to give necessary medications, such as antiplatelets or anticoagulants, to a patient during a coronary artery procedure. The first is by IV; the second is by interrupting the procedure and giving injections through a conventional one lumen catheter,” said David Rott, MD, a cardiologist at Hadassah Hospital. With the new double-lumen device, he noted, “medications can now be delivered directly to the coronary artery without interrupting the procedure and without needing to wait for it to arrive through the blood stream from the IV. This may improve the results of and decrease the dose of medications administered, as necessary drugs may now be dispensed straight to the target area.” According the Hadasit president and CEO Dr. Rafi Hofstein, the innovation has “far reaching” potential to improve outcomes for millions of patients who undergo coronary angioplasty procedures each year. The TTO is now seeking partners to help finance further commercialization efforts. Go to: BusinessWire

Posted September 10th, 2008 under Innovation of the Week, Tech Transfer

Write a comment